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oped repeat transient ischemic attacks following treatment 
attributable to the vascular territories of endovascular treat-
ment. Repeat endovascular treatment was performed in 3 
patients at a mean of 4 months (range = 2–6). Two went on 
to a third endovascular treatment due to progression of dis-
ease in the angioplastied/stented vessel. The average time 
of symptom recurrence after initial endovascular therapy 
was 1.8 months (0–4 months). Follow-up angiography when 
referred to our institution demonstrated 70–90% instent re-
stenosis of the stented vessel in 3 and occlusion in 1 patient. 
Due to persistence of symptoms cerebral revascularization 
was performed in all patients.  Conclusion: MMD is a pro-
gressive angiopathy. Angioplasty and stenting may tempo-
rarily improve the cerebral blood flow and decrease cerebral 
ischemic events but do not appear to be durable nor provide 
long-term prevention against future ischemic events. 
 Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 Moyamoya disease (MMD) is an idiopathic progres-
sive angiopathy typically seen in young adults involving 
the internal carotid artery (ICA) and adjacent middle 
(M1 segment) and anterior (A1 segment) cerebral arteries 
 [1–4] . Segmental changes often begin with focal irregu-
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 Abstract 
 Background: Moyamoya disease (MMD) is an idiopathic pro-
gressive arteriopathy affecting the proximal intracranial vas-
culature. To date only 4 case reports on intracranial angio-
plasty or stenting as treatment of this disease exist. We pres-
ent 5 adult patients with MMD who failed angioplasty and/
or stenting who remained symptomatic despite endovas-
cular treatment or presented with recurrent symptoms
and recurrence of stenosis/occlusion on angiography requir-
ing subsequent extracranial-intracranial revascularization. 
 Methods: Five adult MMD patients who underwent endo-
vascular treatment with angioplasty or stenting were re-
ferred for further evaluation and treatment from outside 
hospitals. Data were collected from clinical referral notes 
and angiograms or reports. All patients underwent repeat 
6-vessel cerebral angiography to assess the extent of disease 
and results of prior endovascular treatment.  Results: Six en-
dovascular procedures were performed in all 5 patients. In-
ternal carotid artery (ICA) balloon angioplasty and Wingspan 
stenting was performed in 2 patients (3 arteries). One patient 
had ICA-M1 angioplasty without stenting. Two patients had 
M1 angioplasty and Wingspan stenting. All patients devel-
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larities isolated to the ICA, which later progress to com-
plete occlusion and development of staged collaterals 
along the circle of Willis.
 No known medical therapy exists to reverse these arte-
rial changes, which can result in progressive ischemia or 
hemorrhage. Endovascular percutaneous balloon angio-
plasty and/or stenting have emerged as viable alternatives 
to surgery for intracranial atherosclerotic disease. The 
success and durability of such techniques for stroke pre-
vention in MMD is unclear. To date there have been 4 
published case reports of endovascular treatment for 
MMD  [5–8] .
 Methods 
 Five MMD patients, with an average age of 33 years (range = 
19–39 years; M:F = 1: 4), underwent endovascular treatment and 
were subsequently referred to our center for further evaluation 
and treatment due to recurrent symptoms. Data were collected 
from available clinical referral notes and from outside angio-
grams or reports. All patients were seen and examined in our 
outpatient clinic. We performed a repeat 6-vessel cerebral angi-
ography to evaluate the extent of disease and results of prior en-
dovascular treatment in all patients.
 Results 
 Table 1 summarizes the lesion locations, symptoms, 
endovascular treatment and outcomes for the patients. 
The 5 patients underwent treatment of 6 lesions. Four 
ICA or combined ICA-M1 lesions were treated in 3 pa-
tients and 2 patients had only M1 stenoses treated. One 
patient underwent angioplasty alone of an ICA-M1 le-
sion. The remainder of the procedures were angioplasty 
with Wingspan stent placement. In 2 of the 5 patients the 
angiopathy was bilateral. One patient with bilateral dis-
ease had treatment of both ICAs. Another with bilateral 
Table 1. M oyamoya patients with failed angioplasty and stenting
Age/
sex
Initial presenting symptoms Stenoses Endovascular treatment Repeat endovascular 
treatment
1 38/F headaches, seizure, bilateral 
watershed infarcts
70% right supraclinoid ICA 
stenosis
ICA-M1 angioplasty and Wingspan 
stent – no residual stenosis
yes/angioplasty of instent 
stenosis
80% left supraclinoid ICA stenosis ICA-M1 angioplasty, Wingspan 
stent – no significant residual 
stenosis
yes/angioplasty of instent 
stenosis
2 39/M headaches, visual disturbances, 
right homonymous 
hemianopsia, PCA infarct
70% left supraclinoid ICA-
proximal M1 stenosis
ICA-M1 angioplasty – no residual 
stenosis
no
3 19/F TIAs: dysarthria, left-sided 
numbness
right supraclinoid ICA occlusion, 
>70% left supraclinoid ICA 
stenosis
ICA angioplasty and Wingspan 
stent – 30% residual stenosis
no
4 32/F right hemiparesis, aphasia 90% left M1 stenosis M1 angioplasty and Wingspan
stent – no residual stenosis
yes/second Wingspan 
inside the first stent for 
instent stenosis
M1 angioplasty for 
recurrence of instent 
stenosis
5 37/F right hemiparesis, aphasia 60–70% left M1 stenosis M1 angioplasty and Wingspan
stent – no residual stenosis
yes/angioplasty of instent 
stenosis
yes/angioplasty of instent 
stenosis
S TA-MCA = Superficial temporal artery to middle cerebral artery; PCA = posterior cerebral artery.
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disease had 1 ICA treated while the other was already oc-
cluded. Moyamoya vessels were present in all patients. All 
patients presented with repeated transient ischemic at-
tacks (TIAs) in the vascular territory of endovascular 
treatment after their initial therapy. All patients showed 
restenosis in the angioplasty and stented segments ( ta-
ble 1 ). 
 Repeat endovascular treatment was performed within 
an average of 3 months (0–6 months) in 3 patients (4 le-
sions). Two of these patients (2 lesions) remained clini-
cally symptomatic despite repeat endovascular treatment 
so that a third endovascular treatment was performed. 
Angiographically one of these patients had a 50% instent 
stenosis at the proximal end of the stent and a 70% steno-
sis distal to the stent. In the other patient there was near 
occlusion of the M1. 
 All patients were symptomatic when referred to our 
institution after their final endovascular therapeutic pro-
cedure. Follow-up angiography at the time of consulta-
tion in our clinic demonstrated 70–90% instent restenosis 
of the stented vessel in 4 patients (5 lesions) and occlusion 
in 1 patient. Due to persistence of symptoms along with 
the progression of stenosis in the endovascularly treated 
vessels, cerebral revascularization was indicated and per-
formed in all patients. 
 All patients underwent unilateral superficial temporal 
artery to middle temporal artery (STA-MCA) bypass in 
the affected hemisphere. Bilateral cerebral revasculariza-
tion (STA-MCA bypass) was performed in 2 patients. All 
patients were asymptomatic without any further TIAs at 
a mean follow-up of 18 months (range = 11–28).
 Two Illustrative Cases 
 Case 1
 A 37-year-old right-handed female presented with left 
hemisphere TIAs manifest as right body numbness, weak-
ness and speech difficulties. She was initially treated with 
clopidogrel bisulfate (Plavix) and aspirin. Angiography 
Time to 
recurrent 
endovascular 
treatment 
months
Recurring 
symptoms in 
territory 
of endovascular 
treatment
Angiographic findings prior to surgical 
treatment
Surgery Clinical follow-up after 
surgical revascularization
3 yes/TIAs 70% instent stenosis – 6 months after 
initial endovascular treatment
right STA-MCA bypass – 9 months 
after last endovascular treatment
asymptomatic, no new strokes 
15 months after bilateral STA-
MCA bypass
4 yes/TIAs 70% instent stenosis – 6 months after 
initial endovascular treatment
left STA-MCA bypass – 8 months 
after last endovascular treatment
yes/TIAs new left PCA stenosis and left M1 
occlusion – 2 months after initial 
endovascular treatment
left STA-MCA bypass – 14 months 
after last endovascular treatment 
asymptomatic, no new strokes 
28 months after left STA-
MCA bypass
yes/TIAs 90% instent stenosis – 3 months after 
initial endovascular treatment, 
additional irregularity of the M1
left STA-MCA bypass – 6 months 
after last endovascular treatment 
(also right STA-MCA bypass at 6 
months) 
asymptomatic, no new strokes 
22 months after bilateral STA-
MCA bypass
2 yes/TIAs mild instent stenosis, 50% stenosis 
proximal to stent, 70% stenosis distal to 
stent – 9 months after initial 
endovascular treatment
left STA-MCA bypass – 3 months 
after last endovascular treatment
asymptomatic, no new strokes 
11 months after left STA-
MCA bypass
7 
6 yes/TIAs near occlusion of M1 – 13 months after 
initial endovascular treatment
left STA-MCA bypass – 5 months 
after last endovascular treatment
asymptomatic, no new strokes 
14 months after left STA-
MCA bypass
8
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showed a 70% left M1 stenosis (with some moyamoya ves-
sels) for which she underwent stenting. Recurrence of 
symptoms and progression of the M1 stenosis was noted 
at 6 months of follow-up and M1 angioplasty was per-
formed. There was no improvement of her symptomatol-
ogy and repeat angiography at 2 months revealed a preoc-
clusive high-grade M1 stenosis, as well as stenosis of the 
proximal M2 segment. She was still on clopidogrel bisul-
fate (Plavix) and aspirin at the time of recurrence of symp-
toms. Reangioplasty of both the M1 and M2 segments was 
performed again without improvement of symptoms. An-
giographic follow-up at 5 months showed near complete 
occlusion of the M1 segment ( fig. 1 ). Due to persistence of 
symptoms and complete M1 occlusion, a left STA-MCA 
bypass was performed. She has remained asymptomatic 
for 14 months since her revascularization surgery.
 Case 2
 A 19-year-old left-handed female with MMD present-
ed at an outside hospital with bihemispheric TIAs with 
slurred speech and transient sensory disturbances of her 
left arm and leg. Angiography showed right ICA occlu-
sion and a  1 70% stenosis of the supraclinoid ICA on the 
left (with some moyamoya vessels). Treatment of the left 
ICA stenosis was recommended at the outside hospital. 
She therefore underwent left ICA percutaneous balloon 
angioplasty and Wingspan stent, which reduced the ste-
nosis to 30%. She was also placed on aspirin and clopido-
grel bisulfate (Plavix). She initially improved, however, 
her TIAs recurred at 3 months when a follow-up angiog-
raphy showed severe restenosis of the left ICA as well as 
mild narrowing and irregularity of the M1 segment 
( fig. 2 ). Due to bilateral disease and recurrence of symp-
A B C
D E F G
 Fig. 1.  A Anteroposterior angiograms of the left ICA. Initial M1 stenosis (arrow).  B Angioplasty and stenting 
showing increased M1 diameter (arrows).  C Recurrence of stenosis at 6 months (arrow).  D Reangioplasty at 6 
months.  E Repeat angiography 2 months later reveals recurrent high-grade M1 and proximal M2 stenoses (ar-
row).  F Reangioplasty of both M1 and M2 (arrow).  G Occlusion of M1 segment prior to revascularization surgery 
(arrow). 
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toms similar to those prior to her initial endovascular 
treatment, bilateral STA-MCA revascularization was 
performed. Her postoperative course has been unevent-
ful at 22 months of follow-up with no recurrent TIAs.
 Discussion 
 MMD is often a bilateral and multifocal angiopathy 
with progression of stenosis/occlusion along the entire 
circle of Willis observed commonly in children and 
young adults  [9–11] . The majority of patients present with 
bilateral symptomatic disease and with impairment in 
cerebral perfusion reserves in both hemispheres. Treat-
ment should therefore aim at alleviating symptoms, pre-
venting stroke in both cerebral hemispheres, and the re-
sults should be durable. Percutaneous balloon angioplas-
ty and/or stenting is appealing as a less invasive treatment 
method to achieve immediate increase in cerebral blood 
flow with a shorter hospitalization time in comparison to 
microsurgical revascularization. 
 There is, however, little documented experience with 
endovascular therapy of MMD. Only 4 previous single 
case reports of MMD angiopathy treated percutaneously 
with balloon angioplasty with or without stenting have 
been described in the literature. Centers may not choose 
to report their limited experience, particularly if the pro-
cedure is not successful. Rodriguez et al.  [8] described a 
37-year-old patient with bilateral ICA stenoses presenting 
with left hemisphere TIAs, where angioplasty of the dis-
tal left ICA and MCA was performed to successfully in-
crease flow. Two-year angiographic follow-up revealed 
decrease in the moyamoya collaterals without evidence of 
restenosis and no recurrence of TIAs. The second case in 
the literature  [7] was an 18-year-old female patient with 
essential thrombocythemia and left hemispheric TIAs. 
Angiography confirmed bilateral MMD involving the 
supraclinoid ICAs and additional involvement of the left 
M1 segment. A stent was placed in the left intracranial 
ICA with resolution of her TIAs. No restenosis was ob-
served at 46 months. The third case was that of a Cauca-
sian MMD twin who underwent angioplasty of a left 
MCA stenosis and Wingspan stenting of a right ICA ste-
nosis  [5] . The left MCA thrombosed on discontinuation 
of clopidogrel bisulfate and the Wingspan stent under-
went instent restenosis requiring repeat angioplasty. 
However, the authors report a 15-month stroke-free in-
terval after the last endovascular treatment.
 A recent fourth case of a 3-year-old girl with moya-
moya syndrome has been reported  [6] . After developing 
acute left hemiplegia she underwent balloon angioplasty 
of a nearly occluded right supraclinoid ICA within 6 h of 
symptom onset with rapid improvement of motor func-
tion and angiographical improvement in the luminal di-
ameter of the right ICA.
 Recognition of the distinct angiographical features of 
MM angiopathy versus atherosclerosis is crucial for cor-
rect management, as both have similar clinical presenta-
A B C
 Fig. 2. Anteroposterior angiograms of the left ICA demonstrating  1 70% stenosis of the supraclinoid ICA ( A , 
arrow) and 30% residual stenosis after stenting ( B , arrow).  C Progression to 90% instent stenosis at 6 months of 
follow-up (arrows). 
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tions but different mechanisms causing intraluminal ste-
noses/occlusion. 
 Previous literature on angioplasty alone for symptom-
atic intracranial atherosclerotic stenosis has shown a high 
rate of technical success with a low rate of subsequent 
stroke  [12, 13] . Reports with the Wingspan stent have 
shown this treatment strategy to have relatively higher 
rates of restenosis for symptomatic intracranial athero-
sclerotic stenoses affecting particularly the supraclinoi-
dal ICA in young patients. These reports suggest that 
these lesions might be of a different nature than the typi-
cal primary atherosclerotic lesions observed in older pa-
tients, that is, they may be of inflammatory origin or may 
simply represent MMD angiopathy  [14–16] .
 Restenoses within a previously angioplastied or stent-
ed segment in all the cases in this reported series may 
reflect a different response in the vessel wall in MMD and 
could be the result of natural progression of disease that 
is characteristic for MMD. Two of our 5 patients showed 
progression of disease unrelated to the site of the angio-
plasty or stent placement (1 in the posterior cerebral ar-
tery and the other in the left M1 prior to cerebral revas-
cularization).
 Surgical revascularization for MMD is safe and effec-
tive in the hands of an experienced surgeon, and results 
in long-term cerebral blood flow augmentation and du-
rable prevention against future TIAs and stroke. The ef-
ficacy of microsurgical revascularization (STA-MCA by-
pass and/or indirect revascularization) for stroke preven-
tion in MMD has been extensively detailed in the 
literature  [2, 17–22] . All patients in this series were
asymptomatic at an average follow-up of 18 months after 
surgery. The limitations of our series include the small 
number of patients initially treated with angioplasty/
stenting, a potential referral bias to Stanford for MMD 
patients who failed angioplasty/stenting and the relative-
ly short follow-up for outcome after revascularization 
surgery.
 Conclusion 
 Percutaneous balloon angioplasty and/or stenting 
may be an attractive, less invasive treatment to achieve 
immediate increase in cerebral blood flow with a shorter 
hospitalization time in comparison to microsurgical re-
vascularization. However, in our small series the recur-
rence of clinical symptoms and evidence of restenosis 
and/or occlusion in previously angioplastied and/or 
stented vessels with an average period of 1.8 months and 
3.9 months, respectively, provides evidence that endovas-
cular treatment is not durable and may not provide long-
term prevention against future ischemic events in MMD.
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